samedan logo

 
 
spacer
home > ebr > spring 2003 > large-scale, comprehensive quality control and analysis of high-throughput screening data
PUBLICATIONS
European Biopharmaceutical Review

Large-Scale, Comprehensive Quality Control and Analysis of High-Throughput Screening Data

High-throughput screening (HTS) is used to search a vast area of the chemical universe for bioactive compounds and provides biological data on different targets from standardised, sensitive and well-controlled experiments for hundreds of thousands of compounds. However, this wealth of information is rarely exploited to its fullest extent and expensive resources are therefore often wasted.

In order to address this problem, intelligent methods and software to process and combine results from different HTS screens, secondary tests and lead profiling experiments are being developed. Data quality, biological side effects and chemical relationships are addressed at every stage, improving guidance for compound selection in screening and optimisation cycles. In support of the screening workflow, the analysis process consists of the following five steps: quality control, standardisation, compound classification, structure-activity relationship (SAR) analysis and pharmacological classification.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Colin J Hardy, Director of Inhalation Studies at Huntingdon Life Sciences

Swen Reimann has a degree in Engineering from the Polytechnicum Winterthur, Switzerland and Hoogeschool Limburg, The Netherlands, as well as a business degree from the University of California Berkeley Extension. He has worked for two leading US software companies in sales and marketing positions prior to joining Genedata in 2001, where he currently serves as a Marketing and Sales Manager for Screener, Genedata's software suite for the scientific analysis of high-throughput screening data.

Michael Lindemann obtained a PhD in Physics from the University of Kiel for his work on multivariate time series analysis applied to human motor control. Previous to this he obtained a MSc from Michigan State University. Dr Lindemann acted as a consultant and IT trainer for several companies prior to joining Genedata in 2001 where he currently serves as Product Manager for Screener.

Bernd Rinn obtained a PhD in Physics from the University of Konstanz for his work on transport and physical ageing in disordered systems. During his studies Dr Rinn gained experience in building and maintaining IT systems for scientific computing and business applications. He joined Genedata in 2001 where he helped in designing and building the Screener system. Currently he leads the development of Screener with a focus on software architecture and algorithms.

Olivier Lefèvre obtained a PhD in Physics from the University of Paris VI for work on neural network models. Prior to this he studied molecular biology and biophysics. For the last eight years he has been working as a software developer, first at NYU Medical School and then at UBS Warburg. He joined GeneData in 2001 where he designed and wrote the AssayAnalyzer module of Screener.

Stephan Heyse earned his PhD in Biophysics from the Swiss Federal Institute of Technology in 1997 for his investigation of functionally active G protein-coupled receptors embedded in supported lipid membranes. He gained practical experience in pharmaceutical high-throughput screening at Bayer AG (Germany), where he headed a screening laboratory. Dr Heyse manages the scientific and technical development of Screener.

spacer
Swen Reimann
spacer
spacer
spacer
Michael Lindemann
spacer
spacer
spacer
Bernd Rinn
spacer
spacer
spacer
Olivier Lefèvre
spacer
spacer
spacer
Stephan Heyse
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement